Glp1 Receptor Agonist Cardiovascular Risk

Exploring the Cardiovascular Risk Profile of GLP-1 Receptor Agonists: A Critical Review

Glucagon-like peptide-1 (GLP-1) receptor agonists have revolutionized the treatment of type 2 diabetes, offering a host of benefits beyond glycemic control, including weight loss and cardiovascular protection. However, recent studies have raised concerns about the cardiovascular risk profile of these medications, particularly when treatment is stopped. In this article, we will delve into the current evidence on glucagon-like peptide-1 receptor agonists and cardiovascular risk.

Background and Mechanism of Action

Glp-1 Receptor Agonist Cardiovascular Risk

GLP-1 receptor agonists mimic the action of GLP-1, a hormone that plays a crucial role in glucose metabolism and cardiovascular health. These medications work by binding to GLP-1 receptors in various tissues, including the pancreas, brain, and cardiovascular system, leading to improved glycemic control, reduced appetite, and slowed gastric emptying, resulting in weight loss and cardiovascular protection.

Cardiovascular Benefits of GLP-1 Receptor Agonists

Numerous studies have demonstrated the cardiovascular benefits of GLP-1 receptor agonists, including reduced risk of heart attack, stroke, and cardiovascular death. These medications have been shown to improve cardiovascular outcomes in patients with type 2 diabetes, heart failure, and peripheral artery disease. For example, a study published in the Journal of the American College of Cardiology found that GLP-1 receptor agonists reduced the risk of major adverse cardiovascular events (MACE) by 27% in patients withtype 2 diabetes.

📁 Category: Risk

🏷️ Tags: #glp-1 receptor agonist cardiovascular risk #glp-1 #receptor #agonist #cardiovascular #risk #configuring g wireless network for smart buildings #nighttime outdoor lighting effects #residential solar panel system installation cost

Gallery Photos

Glucagon-like peptide 1 receptor agonist discontinuation and risks of ...

6 days agoObjectives To characterise patterns of use of glucagon-like peptide1receptoragonists(GLP-1RAs) and assess the associations between variousGLP-1RA treatment scenarios and theriskof major adversecardiovascularevents.Design Target trial emulation.Setting Electronic healthcare databases of US Department of Veterans Affairs,1January 2017 to 31 December 2023. Data obtained from domains in ...

source: https://bmjmedicine.bmj.com

The benefits of GLP1 receptors in cardiovascular diseases

Abstract Glucagon like peptide-1 (GLP-1)receptoragonistsare well established drugs for the treatment of type 2 diabetes (T2D). In addition to glycemic control,GLP-1receptoragonistshave beneficial other effects. They act by binding toGLP-1receptors, which are widely distributed in the body, including cardiomyocytes and blood vessels. The aim of this article is to provide a ...

source: https://pmc.ncbi.nlm.nih.gov

Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists:

Aug 27, 2025Glucagon-like peptide-1receptoragonists(GLP-1RAs) have demonstrated significantcardiovascular(CV) benefits, particularly in patients with diabetes mellitus, but the safety and efficacy of differentGLP-1RAs across diverse populations remain insufficiently defined.

source: https://www.jacc.org

GLP-1 receptor agonists and next-generation incretin-based medications ...

GLP-1receptoragonistswere initially developed to treat type 2 diabetes and have had a transformative effect on its therapy, and are highly effective for glycaemic control, with the added benefit of bodyweight reduction and a lowriskof causing hypoglycaemia.GLP-1receptoragonistsreducerisksfor major adversecardiovascularevents (eg, non-fatal myocardial infarction, stroke, and ...

source: https://www.thelancet.com

Heart Benefits of GLP-1 Medications Fade Shortly After Stopping Therapy

6 days agoNew research shows thatcardiovascularprotection fromGLP-1receptoragonistssuch as semaglutide and tirzepatide diminishes within months of discontinuation.

source: https://www.ajmc.com

GLP-1 Agonists in Cardiovascular Diseases: Mechanisms, Clinical ... - MDPI

Sep 24, 2025Glucagon-like peptide-1 (GLP-1)receptoragonistsnow serve as therapeutic agents forcardiovasculardiseases (CVDs) beyond their original use for treating type 2 diabetes mellitus (T2DM). This review combines molecular mechanisms with clinical evidence to demonstrate howGLP-1agonistshelp lowercardiovascularriskfor conditions, including atherosclerosis, heart failure, stroke, and ...

source: https://www.mdpi.com

Stopping GLP-1 drugs can quickly erase cardiovascular benefits

6 days agoStoppingGLP-1drugs can quickly erasecardiovascularbenefits Even brief interruption tied to change inriskof heart attack, stroke and death by Shawn Ballard • March 18, 2026 Sara Moser and Alaska Adams / WashU Medicine WashU Medicine researchers found that stoppingGLP-1drugs such as semaglutide and tirzepatide — even temporarily — elevates theriskof heart attack, stroke and death ...

source: https://medicine.washu.edu

GLP-1 Receptor Agonists and Cardiovascular Outcomes in Adults With ...

Jan 1, 2026Abstract Glucagon-like peptide-1receptoragonists(GLP-1RAs) provide provencardiovascularbenefits in type 2 diabetes mellitus (T2DM) and heart failure, but their effects in patients with peripheral artery disease (PAD) remain unclear. PAD is common in T2DM and increases theriskof adversecardiovascularand limb outcomes.

source: https://www.ajconline.org

Stopping GLP-1s raises cardiovascular risks: study - CNBC

6 days agoResearch finds that even short gaps in treatment with aGLP-1can drive uprisksof heart attack, stroke and death in patients with Type 2 diabetes.

source: https://www.cnbc.com

GLP-1 Receptor Agonists for the Reduction of Atherosclerotic ...

Patients with type 2 diabetes are at highriskfor development ofcardiovasculardisease, including myocardial infarction, stroke, heart failure, andcardiovasculardeath. Multiple largecardiovascularoutcome trials with novel glucose-lowering agents, namely SGLT2i (SGLT2 inhibitors) andGLP-1RA (GLP-1receptoragonists), have demonstrated robust and significant reductions of major adverse ...

source: https://www.ahajournals.org

Do Heart Benefits of GLP-1 Drugs Last After You Stop? What New Research ...

4 days agoMedications known asGLP-1receptoragonistshave become widely recognized for their role in managing type 2 diabetes and supporting weight loss. Drugs such as semaglutide and tirzepatide are also associated with meaningfulcardiovascularbenefits, including a reducedriskof heart attack and stroke. However, new research suggests that these benefits may not be permanent once treatment stops ...

source: https://www.rejoyhealth.com

"Whiplash": Heart Attack and Stroke Risk Jumps When People Stop Taking ...

6 days agoThey found that theriskof heart attack and stroke jumped in those that pausedGLP-1treatments for as little as six months, compared to those who continued taking the medication. The longer time spent offGLP-1s, the greater theriskof majorcardiovascularevents—up to 22 percent for those who abstained for two years.

source: https://nautil.us

Are GLP-1s everything we hoped for? - Mayo Clinic Press

6 days agoIn the medical field, welcome to acronyms.GLP-1stands for glucagon-like peptide-1, and this is a hormone in the body. When we talk aboutGLP-1sorGLP-1agonistsas a medication, this means that these are manufactured substances that cause the same action in the body as the naturally occurring hormone would. Kristen Meinzer: And how doGLP-1s...

source: https://mcpress.mayoclinic.org

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

Semaglutide, a glucagon-like peptide-1receptoragonist, has been shown to reduce theriskof adversecardiovascularevents in patients with diabetes. Whether semaglutide can reducecardiovascular...

source: https://www.nejm.org

Interrupting or stopping GLP-1s may reverse cardiovascular ... - Healio

TodayStopping or interruptingGLP-1receptoragonists"erode and could ultimately reverse" theircardiovascularbenefits, increasing theriskfor major adversecardiovascularevents, researchers ...

source: https://www.healio.com

GLP-1 Agonists: An Obesity Treatment and Much More

7 days agoThe benefits attributed to glucagon-like peptide-1 (GLP-1)receptoragonistscontinue to accumulate. Initially developed to improve blood sugar control in individuals with type 2 diabetes,GLP-1medications are among the most sought-after drug classes because of their weight-loss capabilities and positive effects on othercardiovasculardisease (CVD)riskfactors. As such, theGLP-1sare as ...

source: https://www.bottomlineinc.com

How does glucagon-like peptide-1 (GLP-1) receptor therapy work in the body?

7 days agoHowGLP-1ReceptorTherapy Works in Your BodyGLP-1receptoragonistswork by activatingreceptorsthroughout your body—primarily in the brain, pancreas, gastrointestinal tract, andcardiovascularsystem—to control blood sugar, reduce appetite, slow gastric emptying, and providecardiovascularprotection.1

source: https://www.droracle.ai

How does Ozempic work? Understanding GLP-1s for diabetes, weight loss ...

Apr 14, 2025GLP-1receptoragonistsalso reduce the likelihood of developing heart-related problems such as heart attacks or strokes. This is an important consideration because diabetes increases heart diseaserisk.

source: https://www.health.harvard.edu

Association Between GLP-1 Receptor Agonists and Worsening Mental Illness

5 days agoTeen cannabis use linked to higherriskof psychotic and mood disorders examines substance-related psychiatricriskfactors in young people. FAQs How doGLP-1receptoragonistswork in the brain?GLP-1receptorsare found not only in the gut and pancreas but also in several brain regions involved in mood, reward, and stress responses.

source: https://drkumardiscovery.com

Comparing Ozempic, Wegovy and Other GLP-1 Drugs - GoodRx

Jan 9, 2026GLP-1agonistdrugs treat diabetes by balancing blood glucose levels. Here's our list ofGLP-1agonists, how they work, similarities and differences, and more.

source: https://www.goodrx.com

Positive and Negative Health Effects from GLP-1 Receptor Agonists

4 days agoDr. Ronald N. Kostoff OVERVIEWGLP-1receptoragonists(e.g., Ozempic, Wegovy, Mounjaro, etc.) have been gaining the public's attention because of effectiveness in promoting weight loss and managing type 2 diabetes, among other benefits. The objective of the present Op-ed is to identify the positive and negative health effects of "Glucagon-Like Peptide-1ReceptorAgonists". Seven AI ...

source: https://www.trialsitenews.com

Adverse Effects of GLP-1 Receptor Agonists - PMC

Current evidence shows thatGLP-1receptoragonistshave no negative effects on thecardiovascularriskof patients with T2D. Thus,GLP-1receptoragonistsappear to have a favorable safety profile, but ongoing trials will further assess theircardiovasculareffects.

source: https://pmc.ncbi.nlm.nih.gov

GLP-1 benefits must be balanced with pancreatitis risk - Healio

6 days agoIn the U.K. alone, more than a thousand reports of pancreatitis associated withGLP-1and dual GLP-1/GIPreceptoragonistshave been reported via the "Yellow Card" scheme since 2007, with 19 ...

source: https://www.healio.com

Semaglutide for weight loss - what you need to know - UCLA Health

ButGLP-1in higher amounts also interacts with the parts of the brain that suppress your appetite and signal you to feel full. When used in conjunction with diet and exercise, it can cause significant weight loss — and a reducedriskof cancer, diabetes and heart disease — in people who are obese or overweight.

source: https://www.uclahealth.org

GLP-1 receptor agonist - Wikipedia

GLP-1agonistswere initially developed to treat type 2 diabetes. [11] The 2025 American Diabetes Association (ADA) standard of care in diabetes includeGLP-1agonistsor SGLT2 inhibitors as a first-line pharmacological therapy for type 2 diabetes in people who have or are at highriskfor atheroscleroticcardiovasculardisease or heart failure. [12] The ADA also recommendsGLP-1agonistsfor ...

source: https://en.wikipedia.org

The Saxenda Solution: Unlocking Weight Loss with GLP-1 Receptor Agonists

1 day agoPhentermine can increase heart rate and blood pressure, making it less suitable for individuals with certain medical conditions. In contrast, Saxenda'sGLP-1receptoragonistmechanism offers a more comprehensive approach to weight loss, addressing hunger, satiety, and metabolism simultaneously.

source: https://leafybark.com

A GoodRx Savings Guide to GLP-1 Receptor Agonists: Ozempic, Wegovy ...

Jan 5, 2026Zepbound (tirzepatide) and Mounjaro (tirzepatide) are considered glucose-dependent insulinotropic polypeptide (GIP)/GLP-1receptoragonists.GLP-1and GIP/GLP-1receptoragonistsare used to treat Type 2 diabetes, lower theriskof majorcardiovascularand kidney-related events, and/or to help people manage their body weight, among other uses.

source: https://www.goodrx.com

Glp-1 Receptor Agonist Cardiovascular Risk

Discovering the Beauty of Glp-1 Receptor Agonist Cardiovascular Risk in Pictures

Exploring the Cardiovascular Risk Profile of GLP-1 Receptor Agonists: A Critical Review

Background and Mechanism of Action

Cardiovascular Benefits of GLP-1 Receptor Agonists

Gallery Photos

Glucagon-like peptide 1 receptor agonist discontinuation and risks of ...

The benefits of GLP1 receptors in cardiovascular diseases

Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists:

GLP-1 receptor agonists and next-generation incretin-based medications ...

Heart Benefits of GLP-1 Medications Fade Shortly After Stopping Therapy

GLP-1 Agonists in Cardiovascular Diseases: Mechanisms, Clinical ... - MDPI

Stopping GLP-1 drugs can quickly erase cardiovascular benefits

GLP-1 Receptor Agonists and Cardiovascular Outcomes in Adults With ...

Stopping GLP-1s raises cardiovascular risks: study - CNBC

GLP-1 Receptor Agonists for the Reduction of Atherosclerotic ...

Do Heart Benefits of GLP-1 Drugs Last After You Stop? What New Research ...

"Whiplash": Heart Attack and Stroke Risk Jumps When People Stop Taking ...

Are GLP-1s everything we hoped for? - Mayo Clinic Press

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

Interrupting or stopping GLP-1s may reverse cardiovascular ... - Healio

GLP-1 Agonists: An Obesity Treatment and Much More

How does glucagon-like peptide-1 (GLP-1) receptor therapy work in the body?

How does Ozempic work? Understanding GLP-1s for diabetes, weight loss ...

Association Between GLP-1 Receptor Agonists and Worsening Mental Illness

Comparing Ozempic, Wegovy and Other GLP-1 Drugs - GoodRx

Positive and Negative Health Effects from GLP-1 Receptor Agonists

Adverse Effects of GLP-1 Receptor Agonists - PMC

GLP-1 benefits must be balanced with pancreatitis risk - Healio

Semaglutide for weight loss - what you need to know - UCLA Health

GLP-1 receptor agonist - Wikipedia

The Saxenda Solution: Unlocking Weight Loss with GLP-1 Receptor Agonists

A GoodRx Savings Guide to GLP-1 Receptor Agonists: Ozempic, Wegovy ...

Related Topics